1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

Siemens Taps Dutch Start-Up ScreenPoint For AI Know-How In Breast Imaging

 
• By Tina Tan

Siemens Healthineers has partnered up with ScreenPoint Medical, a young Dutch company, to codevelop artificial intelligence-based applications in breast-screening. The imaging giant has also taken an equity stake in ScreenPoint.

Siemens Healthineers AG is tapping into the artificial intelligence know-how of ScreenPoint Medical, a spin-out of the Radboud University Medical Center in the Netherlands, to enhance its breast imaging offering.

ScreenPoint, founded in 2014, has developed the Transpara platform that has image analysis and machine learning algorithms to improve the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostic Imaging

More from Diagnostics

Veterinary Heart Health Goes High-Tech: Eko And Boehringer Use AI To Spot Heart Murmurs In Dogs

 
• By Marion Webb

Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 
• By Natasha Barrow

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?